P116 Axillary residual disease in patients with positive sentinel node after neoadjuvant treatment according to tumor subtype

P116 Axillary residual disease in patients with positive sentinel node after neoadjuvant treatment according to tumor subtype

Bibliographic Details
Main Authors:	L. López-Marín, M.L. Arroyo, B. García Chapinal, L. Álvaro, M. Gallego, M.C. Sanz, M. Martínez López, S. Aragón, M. Ciaurriz
Format:	Article
Language:	English
Published:	Elsevier 2023-03-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977623002333

Similar Items

P117 Axillary residual disease after neoadjuvant treatment according to disease burden in the sentinel lymph node biopsy
by: L. López-Marín, et al.
Published: (2023-03-01)

P282 Survival outcomes after neoadjuvant chemotherapy according to the axillary status and tumor subtype
by: L. López-Marín, et al.
Published: (2023-03-01)

Is number of sentinel nodes enougth after neoadjuvant chemotherapy?
by: S. Aragón, et al.
Published: (2021-04-01)

Omitting axillary lymph node dissection in breast cancer patients with metastatic sentinel node after neoadjuvant chemotherapy
by: B. Kuru, et al.
Published: (2021-04-01)

Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer with axillary node metastasis: A survey of clinical practice
by: Sae Byul Lee, et al.
Published: (2019-01-01)

Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial)
by: Amparo Garcia-Tejedor, et al.
Published: (2023-08-01)

P287 Overall survival after neoadjuvant chemotherapy depending on pathological response and tumoral phenotype
by: M. Ciaurriz Gortari, et al.
Published: (2023-03-01)

Quantitative molecular analysis of sentinel lymph node may be predictive of axillary node status in breast cancer classified by molecular subtypes.
by: Simonetta Buglioni, et al.
Published: (2013-01-01)

After neoadjuvant therapy, axillary sentinel lymph node frozen sections from breast cancer patients are accurately diagnosed using telepathology
by: Valarie McMurtry, et al.
Published: (2022-01-01)

IS A COMPLETION AXILLARY DISSECTION NECESSARY FOR PATIENTS WITH METATASIS IN SENTINEL LYMPH NODE?
by: V. Özmen, et al.
Published: (2005-01-01)

Sentinel Lymph Node Biopsy in Breast Cancer: Predictors of Axillary and Non-Sentinel Lymph Node Involvement
by: Hakan Postacı, et al.
Published: (2013-12-01)

Sentinel node biopsy in the breast cancer: Possibility of the avoidance of axillary node dissection
by: Golubović Andrija, et al.
Published: (2002-01-01)

Axillary lymph node dissection could be omitted in the breast cancer patients with a limited sentinel lymph node involvement following neoadjuvant systemic treatment
by: Ana Car-Peterko, et al.
Published: (2021-01-01)

Axillary management still needed for patients with sentinel node micrometastases
by: Cong BB, et al.
Published: (2019-03-01)

Is Pathologic Axillary Staging Valid If Lymph Nodes Are Less than 10 with Axillary Lymph Node Dissection after Neoadjuvant Chemotherapy?
by: Hee Jun Choi, et al.
Published: (2022-11-01)

Regional Recurrence Rates With or Without Complete Axillary Dissection for Breast Cancer Patients with Node-Positive Disease on Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy
by: Diane C. Ling, MD, et al.
Published: (2020-03-01)

P019 Adjuvant chemotherapy after radical surgery and immediate reconstruction
by: M. Ciaurriz Gortari, et al.
Published: (2023-03-01)

Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial
by: Toralf Reimer, et al.
Published: (2020-12-01)

Could axillary lymph node dissection be omitted in the mastectomy patient with tumor positive sentinel node?
by: Ji Young You, et al.
Published: (2023-06-01)

The Accuracy of Sentinel Lymph Node Biopsy Compared with Axillary Lymph Node Dissection in Breast Cancer
by: Abdolrasul Talei, et al.
Published: (2011-10-01)

The analysis of axillary lymph nodes metastasis after neoadjuvant therapy in breast cancer
by: BI Zhao, CHEN Peng, QIU Pengfei, CHEN Yuguang, WANG Yongsheng
Published: (2023-04-01)

Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer
by: Khadidja Brahmi, et al.
Published: (2017-06-01)

The role of breast cancer molecular subtypes in axillary lymph node positivity
by: Mehmet Aslan, et al.
Published: (2023-06-01)

Intra-operative Assessment of Axillary Sentinel Lymph Nodes by Frozen Section—An Observational Study of 260 Procedures
by: Yolanda H.Y. Chan, et al.
Published: (2011-04-01)

Clinical impact of sentinel lymph node biopsy after neoadjuvant treatment in breast cancer patients with initially involved axillary lymph nodes; single-center experience- preliminary analysis
by: Ana Car-Peterko, et al.
Published: (2020-01-01)

Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1–3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study
by: Soong June Bae, et al.
Published: (2024-04-01)

Omission of axillary sentinel lymph node biopsy in early invasive breast cancer
by: Toralf Reimer
Published: (2023-02-01)

Axillary sentinel lymph node biopsy after mastectomy: a case report
by: Hahm George, et al.
Published: (2010-07-01)

Intraoperative predictive model for the detection of metastasis in non-sentinel axillary lymph nodes
by: José Antonio García-Mejido, et al.
Published: (2022-04-01)

Total Tumor Load of mRNA Cytokeratin 19 in the Sentinel Lymph Node as a Predictive Value of Axillary Lymphadenectomy in Patients with Neoadjuvant Breast Cancer
by: Karla B. Peña, et al.
Published: (2021-01-01)

Can axillary radiotherapy replace axillary dissection for patients with positive sentinel nodes? A systematic review and meta-analysis
by: Min Zhao, et al.
Published: (2017-03-01)

Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial
by: Jana de Boniface, et al.
Published: (2017-05-01)

P204 SPECT/CT lymphoscintigraphy can accurately localize the sentinel lymph nodes and the clipped node in breast cancer patients undergoing targeted axillary dissection after neoadjuvant chemotherapy
by: E. Dilege, et al.
Published: (2023-03-01)

THE PREDICTIVE PROBABILITY OF TWO DIFFERENT BREAST CANCER NOMOGRAMS FOR NON SENTINEL AXILLARY LYMPH NODE METASTASIS IN POSITIVE SENTINEL LYMPH NODE BIOPSY
by: Akif Serhat Gür, et al.
Published: (2008-07-01)

Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Axillary Conversion after Neoadjuvant Chemotherapy—A Single-Tertiary Centre Experience and Review of the Literature
by: Alexandra Maria Lazar, et al.
Published: (2023-09-01)

10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection
by: Ian Campbell, et al.
Published: (2023-08-01)

Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,578 patients
by: Siyang Cao, et al.
Published: (2021-10-01)

Synchronous bilateral axillary sentinel lymph node metastases in a patient with truncal melanoma
by: Shena Kravitz, MD, et al.
Published: (2022-08-01)

Use of indocyanine green (ICG) in detection of axillary sentinel lymph nodes for breast cancer
by: C. Nikolaou
Published: (2021-04-01)

The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro‐metastases
by: Gilles Houvenaeghel, et al.
Published: (2023-02-01)